Incyte Corporation (NASDAQ:INCY) had its Buy rating reiterated by Cowen

Analyst Ratings For Incyte Corporation (NASDAQ:INCY)

Story continues below

Today, Cowen reiterated its Buy rating on Incyte Corporation (NASDAQ:INCY).

There are 14 Buy Ratings, 8 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.

The current consensus rating on Incyte Corporation (NASDAQ:INCY) is Buy with a consensus target price of $105.7124 per share, a potential 55.16% upside.

Some recent analyst ratings include

  • 7/31/2018-Cowen Reiterated Rating of Buy.
  • 7/27/2018-Raymond James Reiterated Rating of Buy.
  • 7/13/2018-Morgan Stanley was Downgraded by analysts at Morgan Stanley from a “Overweight ” rating to a ” Equal Weight” rating. They now have a N/A price target on the stock.
  • 6/26/2018-Royal Bank of Canada was Downgraded by analysts at Royal Bank of Canada from a “Outperform ” rating to a ” Sector Perform” rating. They now have a $74.00 price target on the stock, up previously from $76.00 .
  • 6/24/2018-JPMorgan Chase & Co. Reiterated Rating of Buy.
  • 6/11/2018-Evercore ISI Upgrade from a “In-Line ” rating to a ” Outperform” rating.

Recent Insider Trading Activity For Incyte Corporation (NASDAQ:INCY)
Incyte Corporation (NASDAQ:INCY) has insider ownership of 17.20% and institutional ownership of 93.24%.

  • On 7/9/2018 Vijay K. Iyengar, EVP, sold 606 with an average share price of $71.34 per share and the total transaction amounting to $43,232.04.
  • On 5/2/2018 Herve Hoppenot, President, bought 15,000 with an average share price of $60.94 per share and the total transaction amounting to $914,100.00.
  • On 4/30/2018 Paula J Swain, EVP, sold 80,000 with an average share price of $62.43 per share and the total transaction amounting to $4,994,400.00.
  • On 2/21/2018 David W Gryska, Insider, sold 1,952 with an average share price of $85.56 per share and the total transaction amounting to $167,013.12.
  • On 2/21/2018 Reid M Huber, EVP, sold 1,958 with an average share price of $85.55 per share and the total transaction amounting to $167,506.90.
  • On 1/5/2018 David W Gryska, Insider, sold 6,760 with an average share price of $98.87 per share and the total transaction amounting to $668,361.20.
  • On 1/2/2018 Vijay K Iyengar, EVP, sold 5,000 with an average share price of $97.26 per share and the total transaction amounting to $486,300.00.

About Incyte Corporation (NASDAQ:INCY)
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

Recent Trading Activity for Incyte Corporation (NASDAQ:INCY)
Shares of Incyte Corporation closed the previous trading session at 68,03 −0,55 0,80 % with 70.44 shares trading hands.

An ad to help with our costs